Approval, reimbursement and pricing of high-cost cancer medicines in Australia

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical policy and practice 2015-10, Vol.8 (S1), p.O9-O9, Article O9
Main Author: Vitry, Agnes
Format: Article
Language:English
Subjects:
Australian Government
Average Annual Growth Rate
European Medicine Agency
Fund Decision
Oral Presentation
Price Strategy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2549-d78680500da60e4fa664e3e1dd86a31027e533c75c8ca988cec4ce61be6604663
cites
container_end_page O9
container_issue S1
container_start_page O9
container_title Journal of pharmaceutical policy and practice
container_volume 8
creator Vitry, Agnes
description
doi_str_mv 10.1186/2052-3211-8-S1-O9
format article
fullrecord <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_074cadd5d6574cc1bcedd1d1954fd67f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_074cadd5d6574cc1bcedd1d1954fd67f</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_4602342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2549-d78680500da60e4fa664e3e1dd86a31027e533c75c8ca988cec4ce61be6604663</originalsourceid><addsrcrecordid>eNpVkctqwzAQRU1poSHNB3SnD6hbyZZleVMIoY9AaBZp10IejR0Fv5CSQP--clNCM5sZZpjDvdwoumf0kTEpnhKaJXGaMBbLeMPidXEVTc6763_zbTTzfkdDFTlNGZ1EH_NhcP1RNw_EoW3Lg_PYYrcnujNkcBZsV5O-Iltbb2Po_Z6A7gAdadGMR_TEdmR-8HunG6vvoptKNx5nf30afb2-fC7e49X6bbmYr2JIMl7EJpdC0oxSowVFXmkhOKbIjJFCB11JjlmaQp6BBF1ICQgcULAShaBciHQaLU9c0-udCjpb7b5Vr636XfSuVtrtLTSoaM5BG5MZkYUJWAloDDOsyHhlRF4F1vOJNRzK4AqC--DlAnp56exW1f1RcUGTlCcBwE4AcL33DqvzL6NqDEiNAagxACXVhql1kf4ART2FGA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Approval, reimbursement and pricing of high-cost cancer medicines in Australia</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Vitry, Agnes</creator><creatorcontrib>Vitry, Agnes</creatorcontrib><identifier>ISSN: 2052-3211</identifier><identifier>EISSN: 2052-3211</identifier><identifier>DOI: 10.1186/2052-3211-8-S1-O9</identifier><language>eng</language><publisher>BioMed Central</publisher><subject>Australian Government ; Average Annual Growth Rate ; European Medicine Agency ; Fund Decision ; Oral Presentation ; Price Strategy</subject><ispartof>Journal of pharmaceutical policy and practice, 2015-10, Vol.8 (S1), p.O9-O9, Article O9</ispartof><rights>Copyright © 2015 Vitry 2015 Vitry</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2549-d78680500da60e4fa664e3e1dd86a31027e533c75c8ca988cec4ce61be6604663</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602342/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602342/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Vitry, Agnes</creatorcontrib><title>Approval, reimbursement and pricing of high-cost cancer medicines in Australia</title><title>Journal of pharmaceutical policy and practice</title><subject>Australian Government</subject><subject>Average Annual Growth Rate</subject><subject>European Medicine Agency</subject><subject>Fund Decision</subject><subject>Oral Presentation</subject><subject>Price Strategy</subject><issn>2052-3211</issn><issn>2052-3211</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkctqwzAQRU1poSHNB3SnD6hbyZZleVMIoY9AaBZp10IejR0Fv5CSQP--clNCM5sZZpjDvdwoumf0kTEpnhKaJXGaMBbLeMPidXEVTc6763_zbTTzfkdDFTlNGZ1EH_NhcP1RNw_EoW3Lg_PYYrcnujNkcBZsV5O-Iltbb2Po_Z6A7gAdadGMR_TEdmR-8HunG6vvoptKNx5nf30afb2-fC7e49X6bbmYr2JIMl7EJpdC0oxSowVFXmkhOKbIjJFCB11JjlmaQp6BBF1ICQgcULAShaBciHQaLU9c0-udCjpb7b5Vr636XfSuVtrtLTSoaM5BG5MZkYUJWAloDDOsyHhlRF4F1vOJNRzK4AqC--DlAnp56exW1f1RcUGTlCcBwE4AcL33DqvzL6NqDEiNAagxACXVhql1kf4ART2FGA</recordid><startdate>20151005</startdate><enddate>20151005</enddate><creator>Vitry, Agnes</creator><general>BioMed Central</general><general>Taylor &amp; Francis Group</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20151005</creationdate><title>Approval, reimbursement and pricing of high-cost cancer medicines in Australia</title><author>Vitry, Agnes</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2549-d78680500da60e4fa664e3e1dd86a31027e533c75c8ca988cec4ce61be6604663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Australian Government</topic><topic>Average Annual Growth Rate</topic><topic>European Medicine Agency</topic><topic>Fund Decision</topic><topic>Oral Presentation</topic><topic>Price Strategy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vitry, Agnes</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of pharmaceutical policy and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vitry, Agnes</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Approval, reimbursement and pricing of high-cost cancer medicines in Australia</atitle><jtitle>Journal of pharmaceutical policy and practice</jtitle><date>2015-10-05</date><risdate>2015</risdate><volume>8</volume><issue>S1</issue><spage>O9</spage><epage>O9</epage><pages>O9-O9</pages><artnum>O9</artnum><issn>2052-3211</issn><eissn>2052-3211</eissn><pub>BioMed Central</pub><doi>10.1186/2052-3211-8-S1-O9</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2052-3211
ispartof Journal of pharmaceutical policy and practice, 2015-10, Vol.8 (S1), p.O9-O9, Article O9
issn 2052-3211
2052-3211
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_074cadd5d6574cc1bcedd1d1954fd67f
source Publicly Available Content Database; PubMed Central
subjects Australian Government
Average Annual Growth Rate
European Medicine Agency
Fund Decision
Oral Presentation
Price Strategy
title Approval, reimbursement and pricing of high-cost cancer medicines in Australia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A40%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Approval,%20reimbursement%20and%20pricing%20of%20high-cost%20cancer%20medicines%20in%20Australia&rft.jtitle=Journal%20of%20pharmaceutical%20policy%20and%20practice&rft.au=Vitry,%20Agnes&rft.date=2015-10-05&rft.volume=8&rft.issue=S1&rft.spage=O9&rft.epage=O9&rft.pages=O9-O9&rft.artnum=O9&rft.issn=2052-3211&rft.eissn=2052-3211&rft_id=info:doi/10.1186/2052-3211-8-S1-O9&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_4602342%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2549-d78680500da60e4fa664e3e1dd86a31027e533c75c8ca988cec4ce61be6604663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true